Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist
- 17 June 2008
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 105 (24), 8250-8255
- https://doi.org/10.1073/pnas.0709279105
Abstract
1,25-dihydroxyvitamin D(3) (1,25D) regulates gene expression by signaling through the nuclear vitamin D receptor (VDR) transcription factor and exhibits calcium homeostatic, anticancer, and immunomodulatory properties. Histone deacetylase inhibitors (HDACis) alter nuclear and cytoplasmic protein acetylation, modify gene expression, and have potential for treatment of cancer and other indications. The function of nuclear receptor ligands, including 1,25D, can be enhanced in combination with HDACi. We designed triciferol, a hybrid molecule in which the 1,25D side chain was replaced with the dienyl hydroxamic acid of HDACi trichostatin A. Triciferol binds directly to the VDR, and functions as an agonist with 1,25D-like potency on several 1,25D target genes. Moreover, unlike 1,25D, triciferol induces marked tubulin hyperacetylation, and augments histone acetylation at concentrations that largely overlap those where VDR agonism is observed. Triciferol also exhibits more efficacious antiproliferative and cytotoxic activities than 1,25D in four cancer cell models in vitro. The bifunctionality of triciferol is notable because (i) the HDACi activity is generated by modifying the 1,25D side chain without resorting to linker technology and (ii) 1,25D and HDACi have sympathetic, but very distinct biochemical targets; the hydrophobic VDR ligand binding domain and the active sites of HDACs, which are zinc metalloenzymes. These studies demonstrate the feasibility of combining HDAC inhibition with nuclear receptor agonism to enhance their therapeutic potential.Keywords
This publication has 45 references indexed in Scilit:
- Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial ResponseScience, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Sunlight, Vitamin D, and the Innate Immune Defenses of the Human SkinJournal of Investigative Dermatology, 2005
- CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTSAnnual Review of Pharmacology and Toxicology, 2005
- Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell deathCell Death & Differentiation, 2005
- Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cellsOncogene, 2004
- Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53Cancer Gene Therapy, 2000
- AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian CancerScience, 1997
- Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagyCarcinogenesis: Integrative Cancer Research, 1996
- Complementary Effects of Pravastatin and Nicotinic Acid in the Treatment of Combined Hyperlipidaemia in Diabetic and Non-Diabetic PatientsEuropean Journal of Preventive Cardiology, 1994